Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
05 Juin 2023 - 10:01PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
genome editing company focused on developing potentially curative
therapeutics leveraging CRISPR-based technologies, today announced
that Jean-François Formela, M.D. is retiring from its board of
directors, effective June 15, 2023.
"Working with the team at Intellia and seeing the company’s
transformation from an idea to a leader in genome editing has been
one of the most exciting journeys in my career,” said Jean-François
Formela, M.D. “I am confident this is just the beginning for John
and his team. I can’t wait to see Intellia’s next chapter and how
they will transform the future of medicine.”
Dr. Formela was a co-founder of Intellia and has served as a
member of the board of directors since May 2014. Dr. Formela is
currently a partner at Atlas Venture, a life sciences focused
venture capital firm.
“It has been a privilege to serve alongside Jean-François, and I
would like to thank him for both his vision and leadership over the
past decade,” said Intellia President and Chief Executive
Officer John Leonard, M.D. “Jean-François has played an
instrumental role in our mission to advance the development of
CRISPR-based therapies and transform the lives of people living
with severe diseases. On behalf of the Board, we wish him continued
success in his future endeavors.”
About Intellia TherapeuticsIntellia
Therapeutics, a leading clinical-stage genome editing company, is
developing novel, potentially curative therapeutics leveraging
CRISPR-based technologies. To fully realize the transformative
potential of CRISPR-based technologies, Intellia is pursuing two
primary approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the therapy by
using engineered human cells to treat cancer and autoimmune
diseases. Intellia’s deep scientific, technical and clinical
development experience, along with its robust intellectual property
portfolio, have enabled the company to take a leadership role in
harnessing the full potential of genome editing to create new
classes of genetic medicine. Learn more at intelliatx.com. Follow
us on Twitter @intelliatx.
Forward-Looking Statements This press release
contains “forward-looking statements” of Intellia Therapeutics,
Inc. (“Intellia”, “we” or “our”) within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, express or implied
statements regarding Intellia’s beliefs and expectations regarding
our ability to advance the development of our CRISPR-based platform
and programs to transform the future of medicine and the
anticipated contribution of our executives to our operations and
progress. Any forward-looking statements in this press release are
based on management’s current expectations and beliefs of future
events, and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to: the
risk that our CRISPR-based platform and programs will not be
successfully developed and commercialized. For a discussion of
these and other risks and uncertainties, and other important
factors, any of which could cause Intellia’s actual results to
differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in Intellia’s most recent
annual report on Form 10-K and quarterly report on Form 10-Q, as
well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with the Securities
and Exchange Commission. All information in this press release is
as of the date of the release, and Intellia undertakes no duty to
update this information unless required by law.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com
Lina LiSenior Director, Investor Relations and Corporate
Communications+1-857-706-1612lina.li@intelliatx.com
Media:Matt CrensonTen Bridge
Communications+1-917-640-7930media@intelliatx.com
TBCIntellia@tenbridgecommunications.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024